GLP-1 drugs may represent one of the most significant advances in obesity treatment in recent memory. They also serve as a prime example of how pharma marketing can simplify complex medical interventions into sleek consumer offerings.
I’ve been on Mounjaro for almost 5 months. I lost forty pounds, but I noticed that I was losing muscle mass as well. After moving to a better climate, I started cycling again and have ridden over 2,000 miles this year. I understand that the drug is great for lowering my blood sugar, but it, alone, is not the answer. I need exercise as well.
Unfortunately, here is what Americans have heard about GLP-1 drugs like Wegovy and Zepbound: Take the medicine. Eat less food. Lose an incredible amount of weight. See before-and-after photos. Discuss dress sizes, pounds lost, and scale numbers.
What are we talking about less of? Muscle. And that might be one of the GLP-1 era’s great missteps.
When We Celebrate Weight Loss, We’re Not Always Celebrating the Right Thing
When someone loses weight, they haven’t lost 40 pounds of fat. Some of that weight loss is lean tissue. Lean mass loss represents approximately 25% to 39% of total weight loss with incretin-based therapies, according to a 2026 systematic review and meta-analysis involving 20 randomized trials and 15,782 participants. In fact, the estimated proportion of weight loss from lean mass was 35.2% with semaglutide and 25.4% with tirzepatide.
Importantly, significant lean-mass loss also occurs with lifestyle-induced weight loss. Don’t mistake this as evidence that GLP-1 drugs “cause muscle loss.” It’s not what”s happening.
The distinction is important because GLP-1 medications aren’t inherently bad. But weight loss without a plan to preserve muscle is incomplete obesity care.
“A recently published review paper reinforced that GLP-1 treatment is generally associated with greater losses of fat mass compared with lean mass, while also showing measurable decreases in absolute lean mass,” researchers wrote in 2026. They go on to argue that “optimizing” weight loss quality should become the goal: maximizing fat loss while minimizing muscle loss and preserving strength, physical function, and nutritional status.
That’s a very different conversation than celebrating pounds lost.
Where Was That Message in All the Drug Commercials?
This is where I think big pharma deserves criticism. Pharma companies have poured tremendous resources into educating the public about obesity as a chronic disease and the benefits of pharmacologic treatment. But where’s the messaging telling patients exactly how to manage their obesity when they’re taking a GLP-1?
“If you’re taking a GLP-1, here’ how you should be thinking about exercise and nutrition” Should be the pharma industry and physician-community response. Instead, what are we seeing? Images of people happily fitting into old jeans and a miraculous number on the scale. Images and messages meant to drive patients to ask their physicians about these drugs. But nowhere near enough emphasis on how to best manage our health while taking them.
“When we talk about weight loss, we should be referring to fat loss.”
We hear that enough from the scientific community and medical community. Why isn’t it ubiquitous among patients? The American Association of Diabetes spent months writing its 2026 obesity pharmacotherapy standards. Two of many recommendations focused on preserving muscle:
Optimize protein intake and resistance training to help preserve lean mass. Assess muscle strength and function; incorporate aerobic activity for cardiometabolic benefits.
An expert consensus published last year reached similar conclusions, determining that physical activity should be a core component of GLP-1 obesity management. The researchers specifically called out resistance training to help preserve lean body mass.
So why isn’t that as recognizable a phrase to patients as the drug names themselves?
This Is Even Scarier: Patients May Be Moving Less
Some people may lose weight on GLP-1 drugs and move significantly less. Researchers presented this finding at ENDO 2026 after analyzing electronic health records with Fitbit data. They reported that adults who lost weight while on GLP-1 treatments saw a significant decrease in physical activity.
Considering how important movement is for preserving muscle mass during treatment, this should concern everyone. Put simply, we have drugs that can drive unprecedented levels of pharmacologic weight loss. At the same time, some patients may become less active while taking them.
If that doesn’t trigger some sort of industry-wide alarm, we’re missing the point. Big pharma doesn’t need to market GLP-1s as weight-loss drugs. They should be selling them as:
Medication + nutrition + resistance training + cardiovascular exercise + tracking and ongoing monitoring.
“Did you know 65% of patients quit GLP-1s?” seems to be quite a trendy statement in obesity medicine these days. The truth? It varies widely depending on the drug being studied, population, insurance coverage and even definition of what discontinuation means. “65% quit” isn’ going to cut it as a universal number for every drug.
Real-world GLP-1 discontinuation is very real. One Cleveland Clinic analysis from 2026 looked at 7,938 patients who discontinued injectable semaglutide or tirzepatide within 3–12 months of starting. During the subsequent year of follow-up, 19.6% restarted the same medication while another 35.2% initiated another obesity treatment.
This further emphasizes the importance of preparing patients for life on a GLP-1 medication: during treatment, dose changes, insurance changes, side effects, and ultimately medication discontinuation. Patients deserve a plan for what happens next. Providing a prescription without that discussion isn’ comprehensive obesity care.
It’ Time to Stop Selling Weight Loss. Start Selling Better Health.
Let’s pretend for a second that every patient who starts a GLP-1 drug gets this messaging from their health care provider: You need to preserve muscle. Discuss resistance training and view it as a core part of your treatment, not a side hobby. Your diet still matters. Eating fewer calories doesn’t mean you shouldn’t pay attention to nutritional quality. Protein intake is crucial. You shouldn’t stop exercising. You should exercise to get healthy, not to burn calories.
There’s more to your health than weight. Clinicians should track strength, mobility, nutritional status, and body composition, not just BMI and weight.
This may be chronic. Help patients understand that obesity isn’t cured with medication. If they discontinue treatment, there very well may be another medication waiting for them. The beauty? The research suggests this approach to GLP-1 therapy can actually improve the quality of weight loss patients experience. When lifestyle interventions were used alone in the meta-analysis above, lean-mass losses accounted for about 26.2% of total weight lost. When combined with resistance training, that figure dropped to roughly 17.5%.
Pretty impressive. And it deserves far more discussion.
It’s Time for a Round 2 of the GLP-1 Revolution
I get it. Americans, for the most part, want their health problems to be cured by taking a pill or injection. Research continues to show that we don’t get enough exercise, but the message seems to be “take Ozempic, lose weight” rather than “Ozempic along with diet can help you get healthier”.
Mounjaro has given me a tool I didn’t previously have in my obesity-treatment toolbox. But I understand it’s not magical. Nor should they be sold as such. It’s time for round two of the GLP-1 revolution. Instead of telling people these drugs will help them lose weight, let’s show them how to lose weight better.
The other issue is the sycophants on social media, including LinkedIn, who promote pharma’s PR talking points without critical thinking. They show their ignorance by repeating pharma’s marketing statements and rarely think about the strategic positioning and shortcomings.
Pharma has done an incredible job marketing obesity drugs to Americans. The next step? Make sure Americans know how to use those drugs to genuinely improve their health, and that the drug alone won’t lead to good health.
